Cited 1 time in
Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, Songyi | - |
| dc.contributor.author | Shin, Dong-Yeop | - |
| dc.contributor.author | Park, Junseo Steve | - |
| dc.contributor.author | Park, Hee Sue | - |
| dc.contributor.author | Moon, Soo Young | - |
| dc.contributor.author | Yoon, Sung-Soo | - |
| dc.contributor.author | Lee, Dong-Soon | - |
| dc.date.accessioned | 2023-04-27T10:40:31Z | - |
| dc.date.available | 2023-04-27T10:40:31Z | - |
| dc.date.issued | 2022-08 | - |
| dc.identifier.issn | 2077-0383 | - |
| dc.identifier.issn | 2077-0383 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/2777 | - |
| dc.description.abstract | Myelodysplastic syndrome (MDS) is a heterogeneous hematopoietic disorder associated with cellular proliferative and apoptotic activity. We retrospectively investigated these activities in bone marrow samples from 76 MDS patients using immunohistochemical staining for Ki-67 and cleaved caspase-3. We divided cleaved caspase-3 into two groups based on median value and compared the differences according to MDS risk scoring systems. We compared MDS patient indices with idiopathic cytopenia of undetermined significance (ICUS) and healthy control (HC) indices using our previously published data. Cleaved caspase-3 immunohistochemistry was highest in MDS patients, followed by ICUS patients and HCs. Similarly, the mean Ki-67 grade was also highest in MDS patients, followed by ICUS patients and HCs. Higher cleaved caspase-3 grade was significantly associated with lower IPSS-R score (p = 0.020), whereas Ki-67 was not associated with MDS. Interestingly, TET2 mutation was associated with decreased cleaved caspase-3 levels (p = 0.03). However, there was no significant association between proliferative/apoptotic activity and survival. Our results suggest that apoptotic activity gradually increases from healthy controls and ICUS patients to MDS patients. Furthermore, higher apoptotic activity was associated with better MDS patient prognostic scores. Further studies are needed to reveal the differences in apoptotic activity between lower- and higher-risk MDS. | - |
| dc.format.extent | 18 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | MDPI | - |
| dc.title | Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/jcm11154604 | - |
| dc.identifier.scopusid | 2-s2.0-85136484555 | - |
| dc.identifier.wosid | 000838869900001 | - |
| dc.identifier.bibliographicCitation | Journal of Clinical Medicine, v.11, no.15, pp 1 - 18 | - |
| dc.citation.title | Journal of Clinical Medicine | - |
| dc.citation.volume | 11 | - |
| dc.citation.number | 15 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 18 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | General & Internal Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
| dc.subject.keywordPlus | PROGNOSTIC SCORING SYSTEM | - |
| dc.subject.keywordPlus | SYNDROMES MDS | - |
| dc.subject.keywordPlus | MUTATIONS | - |
| dc.subject.keywordPlus | CASPASE-3 | - |
| dc.subject.keywordPlus | CELLS | - |
| dc.subject.keywordAuthor | myelodysplastic syndrome | - |
| dc.subject.keywordAuthor | apoptosis | - |
| dc.subject.keywordAuthor | TET2 mutation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
